MiRXES launches world’s first research project for multi-cancer screening test

Singapore-based MiRXES has launched the world’s first largescale clinical research Project, CADENCE (CAncer Detected Early caN be CurEd). Project CADENCE aims to develop a multi-cancer early detection test for up to nine high incidence and high mortality cancers, including lung, breast, colorectal, liver, stomach (gastric), esophageal, ovarian, pancreatic, and prostate cancers. Project CADENCE is focused to discover and validate novel combinations of bloodborne circulating microRNA (miRNA) and DNA methylation biomarkers for this purpose. It will receive an investment of an estimated S$50 million and more by MiRXES over a three-year period, with substantial in-kind contributions from Singapore’s institutes of higher learning (IHLs) and public healthcare institutions (PHIs). The project will also see the creation of more than 80 new positions in research, manufacturing, and data science over the next three years.